Serological criteria for mild, moderate and severe atrophy in atrophic gastritis.
Secretion of peptide hormones and pepsinogen into the circulation and muriatic acid into gastric lumen decreases at H. pylori - associated atrophic gastritis. The range of these pathophysiological changes depends on affected stomach zone. Atrophy antral mucosa is followed by decrease of gastrin-17 serum rates, especially after nutritive stimulation; gastric corpus atrophy is followed by decrease of pepsinogen-I level. So the comprehensive idea of patient's gastritis nature can be received by definition of gastrin-17 serum rates, pepsinogen-I in a complex with anti- H. pylori IgG level. Results of using testing panel BIOHIT Gastro Panel research groups [1-4] show that contemporary definition of antibodies to H. pylori, gastrin-17 rates and pepsinogen-1 in serum can be used as biomarkers for gastritis and its localization. According to the quoted research's data, it was pointed out that there is a connection between the decrease of gastrin-17 serum rates and pepsinogen-1 and increasing atrophy of mucous membrane, antrum zone u stomach corpus. The results of Sipponen's research [2-4] coincided with the study, which was conducted previously by same scientists [5-7] and also by scientists from different countries [8-14].
Taking into account the known interrelations between the morphological status and functional activity of gastric corpus and antral mucosa and the secretion of, respectively, pepsinogen-1 and postprandial gastrin-17, we carried out a prospective study with the aim detect the optimal boundaries serological markers mild, moderate and severe atrophy of the gastric mucosa.
Materials and Methods
This work has been carried out in accordance with the Declaration of Helsinki (2000) of the World Medical Association. This study was approved ethically by the Ethical committee of Medical Institute, North
Caucasus State Academy of Humanities and Technology (Protocol No: 1/15. Date - 28.01.2015). All patients provided informed written consent.
The study was carried out in a group of 360 dyspeptic Helicobacter pylori-infected patients with age between 16 and 89 years, 236 female and 124 male, have been examined in the Republic of Karachay-Cherkessia, Russian Federation. Results of serological tests of 2 persons were lost. All the 360 patients underwent the upper gastrointestinal endoscopy. Subsequent biopsy of the antral and corpus mucosa was performed for 187 persons. The endoscopy was performed according to the requirements of the Sydney system: 2 biopsy from antrum, 1 biopsy from angulus ventriculi and 2 biopsy from corpus. Biopsy was interrupted in others 173 cases after getting probes from antrum. Markers of antrum atrophy (gastrin-17) and corpus atrophy (pepsinogen-1) are studied separately. Nobody have eradication of H. pylori. Nobody use PPI or H2 blocker.
Markers of mucosal atrophy of the corpus and antrum of the stomach were determined using a test panel for immunoassay "GastroPanel". The set "Gastropanel" (produced by the Finnish company "Biohit") included: a marker of mucosal atrophy antrum gastrin-17 (G-17), a marker of mucosal atrophy of the corpus of the stomach--Pepsinogen-1 (PG-1). HPAb IgG titrers were estimated as follows: < 32 enzyme immunoassay unit (EIU)--negative result, 32-44 EIU--doubtful result, > 44 EIU--positive result.
The pathology of the gastro duodenal area was detected on the basis of a complex of patients' complaints, specific evidence of anamnesis, results of objective and supplementary laboratory examination. In order to identify the content of pepsinogen-1 (PG-1) fasting blood sampling was carried out. The amount of gastrin-17 (G-17) after eating was identified in blood serum samples, which were taken 20 minutes after ingestion of protein dissolved in a beverage (one portion contains 10 g of protein). The samples were subject to centrifugation at 1500 x g for 10 minutes and were thereupon stored at the temperature -20[degrees]C until the conduction of analysis. We use video gastroscope KARLSTORZ with working channel 2, 8 mm and biopsy forceps 2,3 mm.
To increase the accuracy of endoscopic diagnosis, we carried out an additional chromoendoscopy with methylene blue staining allowing the detection of foci of intestinal metaplasia (IM) of gastric mucosa which were unrecognized by routine endoscopy. Biopsy specimens were stained with hematoxylin-eosin and PAS reaction in combination with blue at pH 2,5. The grade of stomach mucosal atrophy was estimated from 0 to 3 according to Houston visual analogous scale. Histological analysis was performed by an independent histologist using a blind method.
Analysis was performed as follows: serological analysis, at first; endoscopy and biopsy, 1 day later; chromo endoscopy 1-2 days later.
Statistical analysis was used to calculate the statistical significance of received data. Pearson's and Spearman's correlation coefficient (r), sensitivity (Se), specificity (Sp), positive predictive value (PPV) and negative predictive value (NPV) of diagnosis by Biohit GastroPanel".
Now used by us test system Biohit GastroPanel" allows to elicit atrophy of the mucous membrane of stomach, but it doesn't show the level of elicited changes. Basing upon our own results, we have worked out functional markers of different levels atrophy of the mucous membrane of antrum and corpus sections of stomach. We have determined average values of serological concentrations of the studied metabolites (gastrin-17 and pepsinogen-1) depending on histological expression level of atrophy of the mucous membrane of stomach. Next, picking the lines of received 95% confidence intervals according to the final Sensitivity and specificity result, we traced marker's lines of a certain level of atrophy of the mucous membrane of the corresponding part of the stomach (Tables 1 and 2). The results of ROC analyses are shown in Figures 1 and 2.
We have conducted a comparative analysis of statistic markers, which describe used methods of research, in order to establish an opportunity to use noninvasive immune ferment analysis method for atrophic and precancerous changes of the mucous membrane of stomach at H. pylori-infection diagnostics. The study demonstrates strong reverse correlation between histological markers of antrum atrophy and gastrin-17 (- 0.73), corpus atrophy and pepsinogen-1 (-0.63).
We have conducted a correlative analysis of the connections between gastrin-17 and pepsinogen-1 rates and other studied parameters (Tables 3 and 4).
According to Table 6, there is a strong inverse correlation between gastrin-17 amount in serum and histological level of antral atrophic gastritis expression (r - 0,85 u r - 0,7). Positively, it characterizes a functional link between these parameters. There is the moderate inverse correlation between gastrin-17 u pepsinogen-1 products. In other cases we can see presence or absence of mild correlation.
According to Table 7, there is a strong inverse correlation between pepsinogen-1 rate in serum u and histological level of corpus atrophic gastritis (r - 0,7; rs - 0,7). Certainly, it characterizes a functional link between these parameters. Moderate direct correlation was elicited between pepsinogen-1 and active and chronic inflammation products (r 0,43 u 0,48; rs 0,48 u 0,58). Similar link can point that it is incorrect to use pepsinogen-1 as a marker corpus atrophic gastritis at active and chronic gastritis, because the screening results will be distorted. So to say, active gastritis is a contraindication to serological screening. In other cases we can see presence or absence of mild correlation.
Further we have conducted a determination of sensitivity and specificity markers, negative and positive predictive value of immunoferment analysis method of "serological biopsy" and diagnostics of atrophic gastritis by determination of gastrin-17 and pepsinogen-1 in serum (Tables 5 and 6).
As shown in Tables 5 and 6, noninvasive detected atrophic gastritis methods, described in this article, have quite high sensitivity at detected non-atrophic and antral severe atrophic gastritis and corpus severe atrophic gastritis, excepting mild antral atrophic gastritis and mild corpus atrophic gastritis cases. Discussed methods have quite high positive predictive value and negative predictive value.
The conducted research has shown that serological markers of functional activity of stomach mucous membrane--pepsinogen-1 and gastrin-17--can serve as the objects of reliable atrophy screening if H. pylori positives have any dispepsic symptoms. Further development of disregeneration and prolipherative processes in stomach mucous membrane in a view of foci intestinal metaplasia, according to our data, isn't followed by statistical important changes of pepsinogen-1 and gastrin-17 at initial phases and is shifting. Thereby, noninvasive screening can't be recommended for timely detection of intestinal metaplasia, in this case choosing method is a chromoendoscopy research of stomach mucous membrane, which can quite reliably detect foci intestinal metaplasia and make pinpoint biopsy for further histological research. So having received the results of serological screening, which significate that a patient has H. pylori associated atrophic gastritis, it is necessary to carry out chromoendoscopy with biopsy from corpus and antrum of stomach. Biopsy is needed to histological detection of precancerous changes of stomach mucous membrane. It should be considered that to determine the risk of stomach cancer development one has to know the rate of atrophy expression. Previously it was possible to determine only with the help of a histological research . All the patients with severe antral atrophic gastritis and severe corpus atrophic gastritis have high risk of gastric cancer. But previously it was impossible to determine such patients by serological atrophy markers gastrin-17 and pepsinogen-1. Now we suggest to use the bounds of serological markers, which we have worked out, for severe antral atrophic gastritis and severe corpus atrophic gastritis to detect patients with high risk of gastric cancer. These patients should have the upper gastrointestinal endoscopy. It allows to detect early gastric cancer after previous effective serological screening. Raising the effectiveness of serological screening, considering also bounds of serological markers of severe antral atrophic gastritis and severe corpus atrophic gastritis, and detecting patients with high risk of gastric cancer will allow to avoid the upper gastrointestinal endoscopy [16-18].
S. Kotelevets performed the clinical research on serological screening of atrophic gastritis. S. Chekh performed the statistical analysis of this clinical research. S. Kotelevets and S. Chekh wrote the manuscript.
[1.] Kotelevets SM, Chekh SA (2014) A comparative study of two methods of serological screening of atrophic gastritis. Biol Med 6: 1-10.
[2.] Sipponen P, Maki T, Ranta P (2001) Application of blood levels of gastrin- 17, pepsinogen-1 and H.pylori antibody for nonendoscopic diagnosis of atrophic gastritis. Presentation delivered at the Digestive Disease Week.--Atlanta, USA.--2001.--Abstracts-On-Disk [R].
[3.] Sipponen P, Harkonen M, Alanko A (2002) Determination of atrophic gastritis from serum samples. Clin Lab 48: 505-515.
[4.] Sipponen P, Valle J, Varis K, Kekki M, Ihamaki T, et al. (1990) Fasting levels of serum gastrin in different functional and morphological states of the antrofundal mucosa. An analysis of 860 subjects. Scand J Gastroenterol 25: 513519.
[5.] Nicolini G, Zagari R, Pozzato P (2002) Diagnosis of atrophic gastritis based upon a combination of three non-invasive tests: Preliminary results of the Loiano-Monghidoro project. J Gastroenterol Hepatol 17
[6.] Sipponen P, Ranta P, Helske T, Kaariainen I, Maki T, et al. (2002) Serum levels of amidated gastrin-17 and pepsinogen I in atrophic gastritis. An observational case-control study. Scand J Gastroenterol 37:785-791
[7.] Vaananen H, Vauhkonen M, Helske T, Kaariainen I, Rasmussen M, et al. (2003) Non-endoscopic diagnosis of atrophic gastritis with a blood test. Correlation between gastric histology and serum levels of gastrin-17 and pepsinogen I: a multicentre study. Eur J Gastroenterol Hepatol 15: 885-891.
[8.] Borch K, Axelsson CK, Halgreen H, Damkjaer Nielsen MD, Ledin T, et al. (1989)The ratio of pepsinogen A to pepsinogen C: a sensitive test for atrophic gastritis. Scand J Gastroenterol 24:870-876.
[9.] Kekki M, Samloff IM, Varis K, Ihamaki T (1991) Serum pepsinogen I and gastrin in screening of severe atrophic corpus gastritis. Scand J Gastroenterol Suppl 186:109-116.
[10.] Miki K, Miki K, Ichinose M, Yahagi N (1977) Efficiency of gastric screening system using serum pepsinogen test. 2nd International Gastric Cancer Congress, Munich, Germany.
[11.] Miki K, Ichinose M, Shimizu A, Huang SC, Oka H, et al. (1987) Serum pepsinogens as a screening test of extensive chronic gastritis. Gastroenterol Jpn 22: 133-141.
[12.] Varis K, Samloff IM, Ihamaki T, Siurala M (1979) An appraisal of tests for severe atrophic gastritis in relatives of pernicious anemia. Dig Dis Sci 24:187-191.
[13.] Westerveld BD, Pals G, Lamers CB, Defize J, Pronk JC, et al. (1987) Clinical significance of pepsinogen A isozymogens, serum pepsinogen A and C levels, and serum gastrin levels. Cancer 59: 952-958.
[14.] Yoshihara M, Sumii K, Haruma K, Kiyohira K, Hattori N, et al. (1998) Correlation of ratio of serum pepsinogen I and II with prevalence of gastric cancer and adenoma in Japanese subjects. Am J Gastroenterol 93: 1090-1096.
[15.] Sipponen P, Kekki M, Haapakoski J, Ihamaki T, Siurala M (1985) Gastric cancer risk in chronic atrophic gastritis: statistical calculations of cross-sectional data. Int J Cancer 35: 173-177.
[16.] Agreus L, Kuipers EJ, Kupcinskas L, Malfertheiner P, Di Mario F, et al. (2012) Rationale in diagnosis and screening of atrophic gastritis with stomach-specific plasma biomarkers. Scand J Gastroenterol 47:136-147.
[17.] Iijima K, Abe Y, Kikuchi R, Koike T, Ohara S et al. (2009) Serum biomarker tests are useful in delineating between patients with gastric atrophy and normal, healthy stomach. World J Gastroenterol: 15:853-859.
[18.] Storskrubb T, Aro P, Ronkainen J, Sipponen P, Nyhlin H, et al. (2008) Serum biomarkers provide an accurate method for diagnosis of atrophic gastritis in a general population: The Kalixanda study. Scand J Gastroenterol 43:1448-1455.
Sergey Mikhailovich Kotelevets * and Sergey Anatolievich Chekh
North Caucasus State Academy of Humanities and Technology, Cherkessk, Russian Federation
* Corresponding author: Sergey M. Kotelevets, Professor, Lenina street, 75/32, Cherkessk, 369000, Russian Federation, Tel: +7-909-495-4749; E-mail: firstname.lastname@example.org
Received March 13, 2015; Accepted April 29, 2015; Published May 06, 2015
Table 1: Border marker of a certain degree of atrophy of the mucous membrane of stomach at antral atrophic gastritis. Grade Atrophy Average 95% [delta] Observation degree value confidence amount intervals 1 No atrophy 18,07 3,88-32,26 7,09 19 2 Mild 8,78 3,83-13,72 2,47 45 3 Moderate 6,03 2,45-9,61 1,79 100 4 Severe 1,42 -1,72-4,55 1,57 194 Grade Postprandial gastrin-17 1 10 [less than or equal to] pmol/l 2 7 [less than or equal to] pmol/l < 10 3 4 [less than or equal to] pmol/l < 7 4 0 [less than or equal to] pmol/l < 4 Table 2: Border marker of a certain degree of atrophy of the mucous membrane of stomach at corpus atrophic gastritis. Grade Atrophy Average 95% [delta] Observation degree value confidence amount intervals 1 No atrophy 110,25 -10,48-230,98 60,37 105 2 Mild 18,71 10,84-26,59 3,94 17 3 Moderate 12,67 1,70-23,64 5,48 37 4 Severe 6,92 2,35-11,49 2,28 26 Grade pepsinogen-1 1 25 [less than or equal to] [micro]g/l 2 15 [less than or equal to] [micro]g/l < 25 3 9 [less than or equal to] [micro]g/l < 15 4 0 [less than or equal to] [micro]g/l < 9 Table 3: Correlation gastrin-17 (pmol/l) to other parameters Pearson's correlation coefficient, r, and Spearman correlation coefficient, [r.sub.s]). Comparative parameters R [r.sub.s] gastrin-17 and antral atrophic gastritis -0,85 -0,7 gastrin-17 and patient's age 0,05 0,06 gastrin-17 end disease durability 0,04 0,04 gastrin-17 and palpation pain 0,06 0,27 gastrin-17 and H. pylori colonization 0,09 0,2 of the gastric mucosa gastrin-17 and activity of gastritis -0,27 -0,26 gastrin-17 and mononuclear infiltration -0,2 -0,13 gastrin-17 and intestinal metaplasia -0,1 -0,06 gastrin-17 and anti-Hp IgG 0,01 0,08 gastrin-17 and dysplasia -0,1 -0,06 gastrin-17 and pepsinogen-1 -0,29 -0,44 Comparative parameters n t gastrin-17 and antral atrophic gastritis 358 17,8 gastrin-17 and patient's age 358 1,11 gastrin-17 end disease durability 358 0,77 gastrin-17 and palpation pain 358 5,23 gastrin-17 and H. pylori colonization 178 2,73 of the gastric mucosa gastrin-17 and activity of gastritis 185 3,63 gastrin-17 and mononuclear infiltration 185 1,81 gastrin-17 and intestinal metaplasia 358 1,21 gastrin-17 and anti-Hp IgG 358 1,55 gastrin-17 and dysplasia 358 1,19 gastrin-17 and pepsinogen-1 358 9,37 Table 4: Correlation pepsinogen-1([micro]g/1) to other parameters (Pearson's correlation coefficient, r and Spearman Correlation coefficient, [r.sub.s]). Comparative parameters r [r.sub.s] pepsinogen -1 and antral atrophic gastritis -0,7 -0,7 pepsinogen -1 and patient's age -0,12 -0,13 pepsinogen -1 end disease durability -0,05 -0,06 pepsinogen -1 and palpation pain -0,06 0,05 pepsinogen -1 and H. pylori colonization -0,13 -0,13 of the gastric mucosa pepsinogen -1 and activity of gastritis 0,43 0,48 pepsinogen -1 and mononuclear infiltration 0,48 0,58 pepsinogen -1 and intestinal metaplasia -0,09 -0,02 pepsinogen -1 and anti-Hp IgG -0,02 -0,02 pepsinogen -1 and dysplasia 0,13 0,2 Comparative parameters n t pepsinogen -1 and antral atrophic gastritis 185 13 pepsinogen -1 and patient's age 358 2,55 pepsinogen -1 end disease durability 358 1,04 pepsinogen -1 and palpation pain 358 0,91 pepsinogen -1 and H. pylori colonization 178 1,72 of the gastric mucosa pepsinogen -1 and activity of gastritis 185 7,42 pepsinogen -1 and mononuclear infiltration 185 9,66 pepsinogen -1 and intestinal metaplasia 358 0,3 pepsinogen -1 and anti-Hp IgG 358 0,35 pepsinogen -1 and dysplasia 358 3,91 Table 5: Sensitivity (Se), Specificity (Sp), Negative Predictive Value (NPV), Positive Predictive Value (PPV) of the method of detected antral atrophic gastritis (Gastrin-17). Antral atrophic Se Sp PPV NPV gastritis (histological) No atrophy 89% 97% 61% 99% Mild 64% 91% 51% 95% Moderate 59% 94% 80% 86% Severe 96% 92% 93% 95% Table 6: Sensitivity (Se), Specificity (Sp), Negative Predictive Value (NPV), Positive Predictive Value (PPV) of the method of detected Corpus atrophic gastritis (Pepsinogen-1). Corpus atrophic Se Sp PPV NPV gastritis (histological) No atrophy 92% 96% 97% 91% Mild 71% 92% 48% 97% Moderate 70% 96% 81% 93% Severe 88% 97% 82% 98% Table 7: Correlation pepsinogen -1 ([micro]g/l) to other parameters (Pearson's correlation coefficient, r, and Spearman correlation coefficient, [r.sub.s]). Comparative parameters r [r.sub.s] pepsinogen -1 and antral atrophic gastritis -0,7 -0,7 pepsinogen -1 and patient's age -0,12 -0,13 pepsinogen -1 end disease durability -0,05 -0,06 pepsinogen -1 and palpation pain -0,06 0,05 pepsinogen -1 and H. pylori colonization -0,13 -0,13 of the gastric mucosa pepsinogen -1 and activity of gastritis 0,43 0,48 pepsinogen -1 and mononuclear infiltration 0,48 0,58 pepsinogen -1 and intestinal metaplasia -0,09 -0,02 pepsinogen -1 and anti-Hp IgG -0,02 -0,02 pepsinogen -1 and dysplasia 0,13 0,2 Comparative parameters n t pepsinogen -1 and antral atrophic gastritis 185 13 pepsinogen -1 and patient's age 358 2,55 pepsinogen -1 end disease durability 358 1,04 pepsinogen -1 and palpation pain 358 0,91 pepsinogen -1 and H. pylori colonization 178 1,72 of the gastric mucosa pepsinogen -1 and activity of gastritis 185 7,42 pepsinogen -1 and mononuclear infiltration 185 9,66 pepsinogen -1 and intestinal metaplasia 358 0,3 pepsinogen -1 and anti-Hp IgG 358 0,35 pepsinogen -1 and dysplasia 358 3,91
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||Research Article|
|Author:||Kotelevets, Sergey Mikhailovich; Chekh, Sergey Anatolievich|
|Publication:||Biology and Medicine|
|Date:||Jul 1, 2015|
|Previous Article:||Advocating for reduced sugar consumption to reduce the prevalence of non-communicable diseases.|
|Next Article:||Prenatal exposures to environmental agents or drugs promote the development of diseases later in life.|